Impath Clients to Benefit from Cell Analysis' QCA System

(New York, NY, USA). Terms were not disclosed.

The QCA system has been cleared by the U.S. Food and Drug Administration (FDA) for estrogen receptor (ER) markers in breast cancer and is awaiting clearance for the oncoprotein Her2/neu. In addition, the system has been designed to analyze all nuclear, membranous, and cytoplasmic immunohistochemical (IHC) markers. The QCA system objectively analyzes tumor cells for predictive and prognostic markers using quantitative image analysis of nuclear and membrane antigens, enabling more precise, targeted therapeutic decision-making.

"QCA is an important new technology that can help improve the quality of information available to pathologists, researchers, and oncologists, so they can make the best decisions for their patients,” explained Joel Herm, CEO of Cell Analysis. The company is a privately held life sciences company that is developing affordable, easy-to-use image analysis tools for studying cancer cells.

"Cell Analysis' QCA system and built-in control of IHC stained tissue slides facilitate reproducibility and rapid turnaround while removing the clinician's perceived limitation of manual inspection,” said Carter H. Eckert, chairman and CEO of Impath. The company states it is in the business of improving outcomes for cancer patients. Its Physician Services uses sophisticated technologies to provide patient-specific cancer diagnostics and prognostic services to pathologists and oncologists.




Related Links:
Impath
Cell Analysis